Faced with the explosive outbreak of COVID-19 across the globe, the biopharmaceutical industry is working with academic institutions and health authorities to develop new therapeutic products and preventive medicines. In this half-day virtual discussion forum, we will look at several ongoing studies on the strategies and progress of product and process development- all within accelerated timeline. Researchers and regulators have taken on this unprecedented challenge with innovative technologies, acceleration and risk-based control strategies. With the sharing of demonstrated ability to shorten development timelines required to bring forward treatment options desperately needed to save lives in this pandemic, we aspire to identify new ideas, effective strategies, and efficient CMC (Chemistry, Manufacturing and Control) practices that can lead to faster development of many other important medicines.
The biopharmaceutical industry has dramatically reduced timelines over the last 10 years through new technologies and processes. To deliver on the urgency of a pandemic, innovators will need to rely on the wealth of expertise in the industry, including CROs and CDMOs, to challenging everything on the critical path to the clinic. Establishing and managing strategic partnerships capable of comprehensive analytics and integrated CRO/CDMO activities will be central to success.